Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
- 1
- 2
Hospital-Treated Gram-Negative Infections | Access and Reimbursement | US | 2016
Gram-Negative Infections | Access & Reimbursement | US examines the market access factors that influence commercial success of therapies for the treatment of gram-negative infections. The analysis…
Gram-Negative Infections | Unmet Need | HABP/VABP Gram-Negative Infections | US/EU | 2016
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are serious hospital-treated infections associated with high rates of multi-drug resistant (MDR) bacteria, including…
MRSA Infections ( How Will U.S. Physician and Payer Receptivity to Novel Therapies Influence the Hospital-Treated Infections Market?) | Physician & Payer Forum | US | 2014
The hospital-treated methicillin-resistant Staphylococcus aureus (MRSA) infection market is dominated by generic vancomycin because of its low cost, physician familiarity and relatively high…
Hospital-Treated Infections (Access to Novel Antibiotics: How Are Payers and Physicians Shaping the Market?) | Physician & Payer Forum | China | 2014
The lackluster global antibiotics pipeline and surge of antibiotic resistance in clinical isolates in China have triggered a new quest for novel antibiotics against complicated HTI. Many local and…
- 1
- 2